Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published June 23, 2015 | Supplemental Material
Journal Article Open

Catalytic in vivo protein knockdown by small-molecule PROTACs


The current predominant therapeutic paradigm is based on maximizing drug-receptor occupancy to achieve clinical benefit. This strategy, however, generally requires excessive drug concentrations to ensure sufficient occupancy, often leading to adverse side effects. Here, we describe major improvements to the proteolysis targeting chimeras (PROTACs) method, a chemical knockdown strategy in which a heterobifunctional molecule recruits a specific protein target to an E3 ubiquitin ligase, resulting in the target's ubiquitination and degradation. These compounds behave catalytically in their ability to induce the ubiquitination of super-stoichiometric quantities of proteins, providing efficacy that is not limited by equilibrium occupancy. We present two PROTACs that are capable of specifically reducing protein levels by >90% at nanomolar concentrations. In addition, mouse studies indicate that they provide broad tissue distribution and knockdown of the targeted protein in tumor xenografts. Together, these data demonstrate a protein knockdown system combining many of the favorable properties of small-molecule agents with the potent protein knockdown of RNAi and CRISPR.

Additional Information

© 2015 Macmillan Publishers Limited. Received 8 May 2015; accepted 3 June 2015; published online 10 June 2015. We thank K. Mueller and D. Poeckel for cell culture support; S. Melchert, E. Stonehouse, A. Lachert, J. Cox, M. Leveridge, C. Pancevac and M. Jundt for biochemistry and sample preparation support; M. Boesche, T. Rudi, M. Kloes-Hudak and K. Kammerer for mass spectrometry support; and S. Gade for data analysis support. This research was partially supported by US National Institutes of Health grants AI084140, T32GM067543 and T32GM007223. Contributions: I.E.D.S., E.K., S.C., A.H.M., J.D.H., D.L.B., J.L.G., L.N.C. and B.J.V. contributed to the design and synthesis of compounds. D.P.B., A.M., K.E.M., N.R., C.C., D.A.G., R.R.W., J.J.F. and W.d.B. contributed to running of in vitro, cellular and in vivo experiments. N.Z., P.G., S.S., G.B., M.F.-S. and M.B. designed, performed and interpreted proteomic analyses. D.P.B., A.M., M.B., P.G., G.B., J.J.F., K.F., L.K., P.S.C., J.D.H., I.C. and C.M.C. designed studies and interpreted results. D.P.B., C.M.C. and I.C. wrote the manuscript. Competing financial interests: A.M., I.E.D.S., S.C., A.M., N.Z., P.G., S.S., G.B., M.F.-S., M.B., L.N.C., B.J.V., K.F., L.K., P.S.C., J.D.H. and I.C. are employees of GlaxoSmithKline. D.A.G., R.R.W. and J.J.F. are employees of Arvinas, LLC. C.M.C. is a shareholder/consultant for Arvinas, LLC and consults for Canaan Partners.

Attached Files

Supplemental Material - nchembio.1858-S1.pdf

Supplemental Material - nchembio.1858-T1.xlsx

Supplemental Material - nchembio.1858-T2.xlsx

Supplemental Material - nchembio.1858-T3.xlsx

Supplemental Material - nchembio.1858-T4.xlsx

Supplemental Material - nchembio.1858-T5.xlsx


Files (25.5 MB)
Name Size Download all
582.1 kB Download
12.6 kB Download
424.0 kB Download
11.3 MB Download
1.8 MB Preview Download
11.2 MB Preview Download
48.1 kB Download

Additional details

August 20, 2023
August 20, 2023